FBIO

Fortress Biotech Inc

FBIO, USA

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

https://www.fortressbiotech.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FBIO
stock
FBIO

Nuvation Bio Stock Surges Amid Price Target Boost TipRanks

Read more →
FBIO
stock
FBIO

Why Is Gene Therapy Focused Senti Bio Stock Falling Today? Benzinga

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$10.75

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.72

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

10.47 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

3.22 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-34.65 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.08

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 18.29% of the total shares of Fortress Biotech Inc

1.

Summit Financial, LLC

(3.4141%)

since

2025/06/30

2.

Vanguard Group Inc

(2.8665%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(1.9669%)

since

2025/07/31

4.

Kestra Advisory Services, LLC

(1.1158%)

since

2025/06/30

5.

Nantahala Capital Management, LLC

(1.094%)

since

2025/06/30

6.

Shikiar Asset Management Inc

(0.9359%)

since

2025/06/30

7.

Geode Capital Management, LLC

(0.7891%)

since

2025/06/30

8.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6737%)

since

2025/07/31

9.

Envestnet Asset Management Inc

(0.5704%)

since

2025/06/30

10.

BlackRock Inc

(0.4439%)

since

2025/06/30

11.

Citadel Advisors Llc

(0.4164%)

since

2025/06/30

12.

Fidelity Extended Market Index

(0.3762%)

since

2025/07/31

13.

CI Private Wealth LLC

(0.3253%)

since

2025/06/30

14.

Northern Trust Corp

(0.3133%)

since

2025/06/30

15.

180 WEALTH ADVISORS, LLC

(0.3127%)

since

2025/06/30

16.

Atria Investments LLC

(0.2985%)

since

2025/06/30

17.

Integrated Wealth Concepts LLC

(0.2285%)

since

2025/06/30

18.

Commonwealth Equity Services Inc

(0.2068%)

since

2025/06/30

19.

PFG Investments, LLC

(0.1863%)

since

2025/06/30

20.

iShares Micro-Cap ETF

(0.1754%)

since

2025/08/31

21.

Panagora Asset Management Inc

(0.1683%)

since

2025/06/30

22.

Fidelity Total Market Index

(0.1673%)

since

2025/07/31

23.

NT Ext Equity Mkt Idx Fd - NL

(0.1542%)

since

2025/06/30

24.

Two Sigma Investments LLC

(0.154%)

since

2025/06/30

25.

Susquehanna International Group, LLP

(0.1534%)

since

2025/06/30

26.

Weaver Consulting Group

(0.151%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.1198%)

since

2025/06/30

28.

Fidelity Series Total Market Index

(0.0975%)

since

2025/07/31

29.

Spartan Extended Market Index Pool F

(0.0853%)

since

2025/07/31

30.

NT Ext Equity Mkt Idx Fd - L

(0.0607%)

since

2025/06/30

31.

Northern Trust Extended Eq Market Idx

(0.0607%)

since

2025/06/30

32.

Spartan Total Market Index Pool G

(0.0428%)

since

2025/07/31

33.

PGIM Quantitative Solutions US Micro Cap

(0.0336%)

since

2025/06/30

34.

Extended Equity Market Fund K

(0.0298%)

since

2025/06/30

35.

Macquarie Healthcare I

(0.0224%)

since

2025/07/31

36.

Fidelity Nasdaq Composite Index

(0.0199%)

since

2025/07/31

37.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0171%)

since

2025/06/30

38.

1290 VT Micro Cap K

(0.0163%)

since

2025/07/31

39.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0145%)

since

2024/12/31

40.

State St US Extended Mkt Indx NL Cl C

(0.0092%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.11

EPS Estimate

-0.01

EPS Difference

0.12

Surprise Percent

1200%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(2)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Moderate Quality(4)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.